SCHEDULE: Citadel Entities Disclose 5.1% Stake in Semler Scientific

Citadel Securities and affiliated entities, including Kenneth Griffin, have disclosed a passive beneficial ownership of 5.1% in Semler Scientific, Inc.

Summary

• Citadel Securities GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, and Kenneth Griffin are jointly filing this Schedule 13G.
• The filing reports beneficial ownership of Common Stock, par value $0.001 per share, of Semler Scientific, Inc.
• As of June 30, 2025, the aggregate amount beneficially owned by Kenneth Griffin and certain Citadel entities is 697,997 shares, representing 5.1% of Semler Scientific's outstanding shares.
• Citadel Securities GP LLC and Citadel Securities Group LP each beneficially own 697,427 shares, representing 5.1% of the class.
• Citadel Securities LLC beneficially owns 635,373 shares, representing 4.6% of the class.
• Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC each beneficially own 570 shares, representing 0.0% of the class.
• All reported shares are held with shared voting and shared dispositive power.
• The percentages are based on 13,688,405 shares outstanding as of June 30, 2025, according to Semler Scientific's Form 8-K filed on August 4, 2025.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative performance indicators or strategic intentions.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance.

Industry Context

This filing indicates a significant passive investment by Citadel, a prominent global financial institution, in Semler Scientific. Such disclosures are common for large institutional investors acquiring stakes above 5% in publicly traded companies, reflecting a market-driven investment rather than a strategic industry move.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Citadel may be viewed positively by some investors as a vote of confidence, while others may note it is a passive investment with no intent to influence control.

Key Dates

Keywords

Semler Scientific, Citadel, Kenneth Griffin, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Passive Stake